Ingen Technologies, Inc.'s Patented Smart Nasal Cannula and Oxyview Increased Market Growth

RIVERSIDE, CA--(Marketwired - November 25, 2013) - Ingen Technologies Inc. (PINKSHEETS: IGNT), (http://ingen-tech.com) the holding company of two subsidiaries; a medical device manufacturing company selling its patented medical products worldwide, and a newly acquired growing telecom business providing services to major telecom companies worldwide, announces today that demand for respiratory devices is fuelled by rising cases of respiratory illnesses, primarily asthma and chronic obstructive pulmonary disease; i.e. chronic bronchitis and emphysema.

“Although our newly acquired Telecom business is on track for future growth, today, we want to speak about the turnaround in our medical division,” stated Gary B. Tilden, Chairman. “Our Oxyview product is finally starting to gain appeal in the respiratory device market which includes ventilators, inhalers, oxygen concentrators, aerosol therapy nebulizers and positive airway pressure devices. We are fortunate that our product reaches these medical, government and commercial markets, such as TopOut where distribution of Oxyview with their high-altitude mountain climbing oxygen systems is a priority. Product diversity is one big advantage to our growing revenue stream since it enhances savings with n-home care services, under the changing healthcare market. We are extremely optimistic about the future of both businesses going forward.”

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: Healthcare Medical Services